Trinity Biotech Accelerates Global Rollout of High-Capacity HbA1c Column System After New Regulatory Clearances

Trinity Biotech ( (TRIB) ) just unveiled an update.

On December 15, 2025, Trinity Biotech announced that it has secured regulatory clearances in multiple countries and expanded the global rollout of its next-generation high-capacity HbA1c column system for its FDA-cleared Premier Hb9210 analyzer, which is now available in more than 10 countries including the United States. The upgraded column technology, aimed at the more than $2 billion and growing global laboratory HbA1c market, delivers up to four times the testing capacity of the existing system, reduces downtime and maintenance through greater column stability, and incorporates new software-driven automation to improve workflow efficiency and cut operating costs for clinical laboratories. By boosting throughput, recurring revenue potential and margins while reinforcing the Premier Hb9210’s positioning as a gold-standard, high-specificity HbA1c platform, the rollout strengthens Trinity Biotech’s competitive foothold in global diabetes care and supports its strategy to deepen market penetration and drive long-term value for stakeholders.

The most recent analyst rating on (TRIB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.

Spark’s Take on TRIB Stock

According to Spark, TipRanks’ AI Analyst, TRIB is a Underperform.

Trinity Biotech’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, negative profitability, and high debt levels. Technical analysis shows mixed signals, with short-term bullish momentum but potential for a pullback. Valuation metrics are unattractive due to negative earnings and lack of dividends.

To see Spark’s full report on TRIB stock, click here.

More about Trinity Biotech

Trinity Biotech plc is a commercial-stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The company develops, acquires, manufactures and markets diagnostic systems—reagents and instruments—for point-of-care and clinical laboratory markets, with products used to detect infectious diseases and measure HbA1c and other chemistry parameters in blood. Trinity Biotech sells directly in the United States and via distributors and strategic partners in more than 75 countries, and has recently entered the wearable biosensor space through the acquisition of Waveform Technologies’ biosensor assets, aiming initially at continuous glucose monitoring devices and services.

Average Trading Volume: 103,019

Technical Sentiment Signal: Sell

Current Market Cap: $17.19M

For detailed information about TRIB stock, go to TipRanks’ Stock Analysis page.